Latest Breaking News On - Olopatadine hydrochloride ophthalmic solution - Page 1 : comparemela.com

Mumbai (Maharashtra) [India]/ Mahwah (New Jersey) [US], June 28 (ANI/PRNewswire): Glenmark Pharmaceuticals Ltd., an innovation-driven, global pharmaceutical company, announced that its fully owned subsidiary Glenmark Pharmaceuticals Inc., USA (Glenmark) has acquired the approved Abbreviated New Drug Applications (ANDAs) for Famotidine Tablets USP, 10 mg and 20 mg (OTC), Cetirizine Hydrochloride Tablets USP, 5 mg and 10 mg (OTC), Lansoprazole Delayed-Release Capsules USP, 15 mg (OTC) and Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1 per cent (OTC) in the United States from Wockhardt Limited.

United statesSanjeev krishanStates glenmarkBiosimilars companiesLinkedin glenmark pharmaceuticalsGlenmark pharmaceuticals incGlenmark pharmaceuticals ltdNew jerseyAbbreviated new drug applicationsFamotidine tabletsCetirizine hydrochloride tabletsLansoprazole delayed release capsulesOlopatadine hydrochloride ophthalmic solutionPharmaceutical salesDow jones sustainability indexSocial media